Research Analysts Issue Forecasts for Pharvaris Q4 Earnings

Key Points

• HC Wainwright forecasts Pharvaris will lose $0.65 per share in Q4 2027 and projects FY2030 earnings of $6.60 per share; it maintains a “Buy” rating.
• Analyst sentiment is generally positive, with an overall “Moderate Buy” consensus and an average price target of $51.08, despite some “Sell” ratings.
• Pharvaris recently reported a quarterly loss of $0.81 per share, missing expectations by $0.06, while insiders sold $5.3 million of shares over the past three months.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Research analysts at HC Wainwright issued their Q4 2027 earnings estimates for Pharvaris in a research note issued on Friday, August 14th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.65) per share for the quarter. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Pharvaris' FY2030 earnings at $6.60 EPS.

A number of other equities analysts have also recently weighed in on PHVS. Wells Fargo & Company initiated coverage on Pharvaris in a report on Wednesday, July 15th. They issued an "overweight" rating and a $55.00 price target for the company. New Street Research set a $60.00 price objective on Pharvaris in a research note on Friday. Wall Street Zen cut Pharvaris from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a research note on Friday, July 17th. Finally, Royal Bank Of Canada upped their target price on shares of Pharvaris from $51.00 to $52.00 and gave the company an "outperform" rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has an average rating of "Moderate Buy" and an average target price of $51.08.

Pharvaris Stock Performance

PHVS stock opened at $35.14 on Monday. The stock's 50 day moving average price is $33.71 and its 200 day moving average price is $30.11. The firm has a market cap of $2.30 billion, a P/E ratio of -11.52 and a beta of -2.31. Pharvaris has a 1 year low of $20.65 and a 1 year high of $36.93.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06).

Insider Buying and Selling

In other Pharvaris news, CFO David W. Nassif sold 10,000 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.31, for a total transaction of $303,100.00. Following the transaction, the chief financial officer owned 120,300 shares of the company's stock, valued at $3,646,293. This represents a 7.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Anne Lesage sold 30,703 shares of the firm's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the sale, the insider owned 93,969 shares in the company, valued at $3,334,959.81. This trade represents a 24.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 156,030 shares of company stock worth $5,304,914 in the last three months.

Institutional Trading of Pharvaris

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in shares of Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock valued at $952,000 after acquiring an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi grew its holdings in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company's stock valued at $489,000 after purchasing an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company's stock valued at $860,000 after purchasing an additional 7,879 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source